A Phase 1/2 interventional study of Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin) in Chronic Lower Back Pain (CLBP), sponsored by University of Maryland, Baltimore. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Maryland, Baltimore · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 712 studies in Low Back Pain with a site in United States, this one is the 245th largest by planned enrollment of the 623 interventional ones that give a count, is one of 4 that started in 2027, is one of 10 in phase 1/2, reaches primary completion later than 123 of the 125 other live ones, and was the 707th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
712 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 4 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 90 across the 85 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 712 have an industry lead sponsor. The 10 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
University of Maryland, Baltimore has 2 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
52 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 52 to your calendar (.ics) → With an account.
Among the 712 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-group, within-subject, double-blind, double-dummy, placebo-controlled study evaluating whether gabapentin (Neurontin) changes the analgesic, safety, and subjective effects of the opioid hydromorphone (Dilaudid) when the two are combined.
This is a human laboratory systematic examination of whether adding the FDA-approved gabapentin (Neurontin; oral) to the FDA-approved opioid hydromorphone (Dilaudid; oral) will change the experience of hydromorphone as rated by laboratory measures of pain, subjective reports of drug effects, and cognitive performance. Subjects are healthy individuals with chronic lower back pain and no history of substance use disorder. Study subjects and staff are blinded to the study drugs and the class of drugs under investigation and are informed that subjects may receive opioids, stimulants, gabapentinoids, cannabinoids, benzodiazepines, over the counter medications, and/or placebo. Sessions last up to 8-hours in an outpatient setting. Primary outcomes are collected from participants prior to dosing and at several hour periods post-dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0mg oral hydromorphone, 0mg oral gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
4mg oral hydromorphone, 300mg oral gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
4mg oral hydromorphone, 900mg oral gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
0mg oral hydromorphone, 300mg oral gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
0mg oral hydromorphone, 900mg oral gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
4mg oral hydromorphone, 0mg gabapentin
Drug: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin)
Within-subject double-blind, double-dummy, study design wherein all participants received all drug combinations (Placebo + Placebo, Hydromorphone + Placebo, Low Dose Gabapentin + Placebo, High Dose Gabapentin + Placebo, Low Dose Gabapentin + Hydromorphone, High Dose Gabapentin + Hydromorphone) in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Peak change from baseline Drug Effect
Peak self-reported "Drug Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Drug Effect" on a visual anaogue scale (0-100)
Time frame: 8 hour study sessions
Peak change from baseline Good Effect
Peak self-reported "Good Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Good Effect" on a visual anaogue scale (0-100), where lower scores indicate no effect and greater scores indicate maximum effect.
Time frame: Baseline (0.5 hours before drug administration) and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 8 hours after drug administration
Peak Cold Pressor Test Tolerance change from baseline score
Peak Cold Pressor Test Tolerance Score minus baseline Peak Cold Pressor Test Tolerance score. Outcome ranges from 0-60 seconds, 0 indicating low analgesic effect and 60 indicating high analgesic effects.
Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration
Peak Cold Pressor Test Threshold change from baseline score
Peak Cold Pressor Test Threshold Score minus baseline Peak Cold Pressor Test Threshold score. Outcome ranges from 0-60 seconds, 0 indicating low analgesic effect and 60 indicating high analgesic effects.
Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration
Peak Heat Pain with Capsaicin Threshold change from baseline score
Peak Heat Pain with Capsaicin Threshold score minus baseline Peak Heat Pain with Capsaicin Threshold score. Outcome ranges from 0-100, 0 indicating no pain and 100 indicating extreme pain.
Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration
Peak Heat Pain with Capsaicin Tolerance Change from Baseline Score
Peak Heat Pain with Capsaicin Tolerance score minus baseline Peak Heat Pain with Capsaicin Tolerance score. Outcome ranges from 0-100, 0 indicating no pain and 100 indicating extreme pain.
Time frame: Baseline (0.5 hours before drug administration) and 4 and 6 hours after study drug administration
Peak change from baseline Bad Effect
Peak self-reported "Bad Effect" on a visual analogue scale (0-100) minus baseline ratings of self-reported "Bad Effect" on a visual anaogue scale (0-100) where lower scores indicate no effect and greater scores indicate maximum effect.
Time frame: Baseline (0.5 hours before drug administration) and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, and 8 hours after drug administration
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2032, 60 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maryland, Baltimore →